Beloren | Updates

By Sven Schimansky-Wabra

Degode receives next confirmation from European regulatory authorities


Dear Companists,

Many thanks for the EUR 500,000, which we have reached very quickly.


Formula obtains 7th confirmation and study waiver

In keeping with the good news, our formula also obtained the seventh confirmation from an EU authority and the approval of the study waiver.

The current status of FDA approval met with great interest. Here we can inform you that we have almost finalized the FDA documents for consultation with the US authorities and will soon submit them to the FDA. We will inform you about this again in future.

After intensive preliminary negotiations and a first personal meeting in Madrid at the CPHI, we will conduct a personal final negotiation with the planned US partner this year in the US.

A second potential licensing partner for South America showed interest at BIO Europe last week and is thus stimulating the competition. Either the highest bidder will be accepted, or it will possibly even be awarded semi-exclusively.


Financing target reached, next target is the limit

We recently reached our financing target of EUR 500,000. Having said that, we still want to collect the EUR 700,000 announced in the Investment Information Sheet. Every euro helps DEGODE to build on a healthy capital base. Naturally, shares are made available according to the calculation, so that everyone receives the same quota depending on the investment.

The additional EUR 200,000 will enable us to examine the short-term inclusion of a second product from the portfolio we have already scanned. Although it is smaller than Skinoren, it is also a semi-solid and prescription product. It would be very cost-neutral to implement it considering the existing synergies in development & production.


DEGODE is making inroads into digitization

Database searches have a large share in the development activity. DEGODE no longer carries these out manually on databases it knows; the search is now automated by licensed software on all available databases worldwide. In the end, of course, manual control is still necessary, but this way search processes can be represented extremely effectively, as several hundreds of pharmaceutical databases can be searched simultaneously.

Unfortunately, no newer market data relating to the last update is yet available via the Global Data Databases.

Best greetings,



Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 700,000




19.23 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Beloren.
Already registered?    Log in